

Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease

NCT07242222

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Tanta University
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (1)

- Either male or female adult patients (>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography (US).

Exclusion (3)

- Pregnant and/or lactating women, excessive alcohol use (defined as an average alcohol intake > 30 g per day in men and > 20 g per day in women).
- Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, and autoimmune hepatitis.
- Patients suffering from chronic kidney disease, hyper/hypoparathyroidism. Hypersensitivity to erdosteine.

Locations (1 total)

Tanta University, Tanta, Egypt